Ida Shaef

Ida Shaef currently serves as the Chief Strategy Officer (CSO) at PRAMOMOLECULAR, where she plays a pivotal role in shaping the company's strategic direction within the rapidly evolving field of RNA interference (RNAi) therapeutics and therapeutic oligonucleotides (TONs). With her extensive expertise in molecular biology and biochemistry, Ida leads the development and execution of innovative strategies to advance PRAMOMOLECULAR’s pipeline of targeted gene-silencing therapies. Her focus is on optimizing delivery platforms for TONs, ensuring efficient cellular uptake and stability, which are critical for translating RNAi technologies into viable clinical solutions.

In her role, Ida oversees key projects that leverage cutting-edge delivery systems, such as lipid nanoparticles and conjugation strategies, to enhance the therapeutic potential of oligonucleotides. She collaborates closely with research and development teams to refine molecular design, improve pharmacokinetics, and address challenges related to off-target effects and immune responses. Her expertise in quality assurance ensures that all therapeutic oligonucleotides meet stringent regulatory standards, facilitating smooth progression from preclinical studies to clinical trials.

Ida’s strategic initiatives also include forging partnerships with biotech and pharma companies to accelerate the commercialization of RNAi-based therapies. Her deep understanding of the molecular mechanisms underlying RNAi, combined with her leadership in biochemistry and oligonucleotide delivery, positions PRAMOMOLECULAR at the forefront of precision medicine. Through her visionary approach, Ida Shaef continues to drive innovation in therapeutic oligonucleotides, aiming to deliver transformative treatments for genetic and acquired diseases.